Thomas Taynton
PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia
Taynton, Thomas; Barlow, Gavin; Allsup, David
Authors
Gavin Barlow
Dr David Allsup D.J.Allsup@hull.ac.uk
Senior Lecturer in Haematology and Honorary Consultant
Abstract
Mould-active antifungal prophylaxis is frequently used to prevent invasive fungal infection in patients with acute leukaemia being treated with intensive chemotherapy. Invasive fungal infections are difficult to diagnose, and despite the use of prophylaxis a high proportion of patients still receive therapeutic antifungals. Antifungal medications have important interactions, can cause serious adverse events, and may drive the proliferation of antifungal resistance. The use of two biomarkers, such as galactomannan in combination with the less-specific β-d-glucan, can mitigate the risk of not detecting non-Aspergillus species, as well as improving pooled sensitivity and specificity. We argue that regular biomarkers could be used safely as part of an antifungal stewardship strategy to reduce antifungal use, by both screening for infection in patients not on prophylaxis and ruling out infection in patients treated empirically.
Citation
Taynton, T., Barlow, G., & Allsup, D. (2022). PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia. JAC-Antimicrobial Resistance, 4(4), Article dlac074. https://doi.org/10.1093/jacamr/dlac074
Journal Article Type | Article |
---|---|
Acceptance Date | Jun 7, 2022 |
Online Publication Date | Jul 22, 2022 |
Publication Date | Aug 1, 2022 |
Deposit Date | Jul 25, 2022 |
Publicly Available Date | Oct 27, 2022 |
Journal | JAC-Antimicrobial Resistance |
Print ISSN | 2632-1823 |
Electronic ISSN | 2632-1823 |
Publisher | Oxford University Press |
Peer Reviewed | Peer Reviewed |
Volume | 4 |
Issue | 4 |
Article Number | dlac074 |
DOI | https://doi.org/10.1093/jacamr/dlac074 |
Keywords | General Medicine |
Public URL | https://hull-repository.worktribe.com/output/4040396 |
Additional Information | Issue Section: For Debate |
Files
Published paper
(226 Kb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0
Copyright Statement
©The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
You might also like
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia
(2022)
Journal Article
Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia
(2022)
Journal Article